Page last updated: 2024-11-06

ethinylestradiol-3-sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ethinylestradiol-3-sulfate: binds to albumin at 2 sites [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68575
CHEMBL ID1614648
CHEBI ID136600
SCHEMBL ID349803
MeSH IDM0085619

Synonyms (21)

Synonym
ethynylestradiol sulphate
ethinyl estradiol sulfonate
24560-70-1
ethinylestradiol-3-sulfate
(17alpha)-17-hydroxy-19-norpregna-1,3,5(10)-trien-20-yn-3-yl hydrogen sulfate
CHEBI:136600
17alpha-ethynylestradiol sulfate
17alpha-ethinylestradiol 3-sulfate
[(8r,9s,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
CHEMBL1614648
19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-(hydrogen sulfate), (17alpha)-
ethynylestradiol-3-sulfate
unii-67p0fm71oz
67p0fm71oz ,
SCHEMBL349803
17.alpha.-ethynylestradiol 3-sulfate
19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-(hydrogen sulfate), (17.alpha.)-
ethynylestradiol 3-sulfate
DTXSID80873219
Q27264157
19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-(hydrogen sulfate), (17?)-

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The analysis of the plasma concentrations obtained after administration of EE-3 and EE-17 indicates significant differences in their pharmacokinetic profiles."( Human pharmacokinetics of ethynyl estradiol 3-sulfate and 17-sulfate.
Dorantes, A; Goldzieher, JW; Mileikowsky, G; Newburger, J; Stavchansky, SA,
)
0.13
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of orally administered EE2 was about 60%, confirming the presence of a substantial first-pass effect."( The pharmacokinetics and metabolism of ethinyl estradiol and its three sulfates in the baboon.
Castracane, VD; Goldzieher, JW; Moore, PH; Newburger, J; Williams, MC, 1983
)
0.27
"The impact of intestinal conjugative metabolism on oral bioavailability was assessed by sequential and simultaneous analyses of the reported data in humans."( Differentiation of organ availability by sequential and simultaneous analyses: intestinal conjugative metabolism impacts on intestinal availability in humans.
Hayashi, M; Kawashima, K; Mizuma, T; Sakaguchi, S; Sakai, S, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
" The weekly dosage of 2 mg Turisteron led to a decrease of the biologically active, free testosterone to less than 2% compared with the initial value."( [Conservative therapy of prostate cancer using Turisteron].
Dörner, G; Guddat, HM; Rohde, W; Schnorr, D; Stahl, F, 1987
)
0.27
"45 patients with prostatic cancer were treated conservatively with Turisteron at a dosage of 2 mg per week."( [Behavior of LH, FSH, total testosterone, free testosterone and SHBG serum levels in the therapy of prostatic cancer with Turisteron (ethinyl estradiol sulfonate)].
Dörner, G; Guddat, HM; Rohde, W; Schnorr, D; Stahl, F, 1987
)
0.27
" As a result the use of Cytonal at least in the dosage hitherto used is no longer worth being advocated."( [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
Fiedler, R; Klebingat, KJ; Lorenz, G; Panzig, E; Steinhauser, I, 1987
)
0.27
" With a dosage of 2 mg per week it shows a distinct antigonadotropic and antiandrogenic effect."( [Clinical study of ethinyl estradiol sulfonate in conservative therapy of prostate cancer].
Dörner, G; Guddat, HM; Rhode, W; Schnorr, D; Stahl, F, 1987
)
0.27
" After a 6 to 8 weeks treatment at a dosage of one milligram weekly a DEI of 7,27 (+/- 0,74) was attainable."( [Effect of ethinyl estradiol sulfonate on the urethral epithelium after bilateral oophorectomy].
Kindt, J; Retzke, U; Scheunert, EU, 1984
)
0.27
" After oral dosage administration, the 3-glucuronide and, in some cases, the 3,17-diglucuronide also become important."( The pharmacokinetics and metabolism of ethinyl estradiol and its three sulfates in the baboon.
Castracane, VD; Goldzieher, JW; Moore, PH; Newburger, J; Williams, MC, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
estrogenA hormone that stimulates or controls the development and maintenance of female sex characteristics in mammals by binding to oestrogen receptors. The oestrogens are named for their importance in the oestrous cycle. The oestrogens that occur naturally in the body, notably estrone, estradiol, estriol, and estetrol are steroids. Other compounds with oestrogenic activity are produced by plants (phytoestrogens) and fungi (mycoestrogens); synthetic compounds with oestrogenic activity are known as xenoestrogens.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
steroid sulfateA sulfuric ester obtained by the formal condensation of a hydroxy group of any steroid with sulfuric acid.
17beta-hydroxy steroidA 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-199029 (63.04)18.7374
1990's2 (4.35)18.2507
2000's5 (10.87)29.6817
2010's7 (15.22)24.3611
2020's3 (6.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.91 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (8.16%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (91.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]